Cargando…
Locally advanced undifferentiated small round cell sarcoma of the lung with novel SDCCAG8-AKT3 fusion and type II tumor immunity in the microenvironment: a rare case report
BACKGROUND: Despite significant recent advances in characterizing the molecular pathogenesis of undifferentiated small round cell sarcoma (USRCS), rare cases without reported gene alterations remain unclassified. To date, the efficacy and prognostic biomarker of immunotherapy in the treatment of unr...
Autores principales: | Huang, Lin, Qin, Changlong, Pu, Dan, Liu, Yanyang, Bassi, Massimiliano, Käsmann, Lukas, Li, Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459619/ https://www.ncbi.nlm.nih.gov/pubmed/36090644 http://dx.doi.org/10.21037/tlcr-22-572 |
Ejemplares similares
-
Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
por: Zhai, Xiaoqian, et al.
Publicado: (2022) -
Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
por: Gu, Xiaodong, et al.
Publicado: (2022) -
Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022) -
High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
por: Li, Yan, et al.
Publicado: (2022) -
A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report
por: Xu, Fangye, et al.
Publicado: (2022)